Patients with benign asbestos-associated pleural disease and patients with suspected mesothelioma Cancer Malignant neoplasm of lung
Conditions
Interventions
Arm A will follow patients up over a 2-year period following an initial benign pleural biopsy. All patients will have their initial pleural biopsies retrieved and banked and all will have baseline ris
Sponsors
NHS Greater Glasgow and Clyde
Eligibility
Sex/Gender
All
Age
16 Years to 120 Years
Inclusion criteria
Inclusion criteria: Arm A: 1. History of asbestos exposure or imaging compatible with this (e.g., pleural plaques) 2. Any form of pleural biopsy within the last 1 year showing evidence of associated pleural inflammation (e.g., benign fibrinous pleurisy, non-specific pleuritis, atypical mesothelial proliferation) 3. Informed written consent (to at least banking of previous and future pleural tissue samples) Arm A MRI sub-study: 1. Registered to Arm A 2. Informed written consent Arm B: 1. Suspected pleural malignancy, defined by a unilateral pleural effusion or mass 2. History of asbestos exposure or typical radiological features, e.g., pleural plaques 3. Sufficient fitness for thoracoscopy (LAT or VATS are permissible) 4. Informed written consent Added 21/08/2025: Arm A and B: =16 years of age
Exclusion criteria
Exclusion criteria: Arm A: 1. Any cytologically or histologically confirmed pleural malignancy 2. Any pleural infection including TB 3. Granulomatous pleural inflammation 4. Any specific pleuritis (e.g., RA) 5. Previous pleurodesis Arm A MRI sub-study: 1. Any contraindication to MRI, e.g., claustrophobia, pregnancy, metallic foreign body, pacemaker/implant 2. Allergy to gadolinium contrast 3. eGFR <30 ml/min Arm B: 1. Current or recent (within the last 3 months) intercostal chest drain 2. Previous pleurodesis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients in Arm A diagnosed with malignant pleural mesothelioma based on histological confirmation in tissue biopsies at any point from study registration to completion of 2 years follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Results of a multiomic risk classifier based on radiomics based on perfusion MRI early contrast enhancement, proteomic assay to be confirmed, exhaled breath metabolomics by gas chromatography-mass spectrometry at baseline in Arm A 2. Number of patients in the Arm B with histologically confirmed malignant pleural mesothelioma following thoracoscopy | — |
Countries
England, Scotland, United Kingdom, Wales
Contacts
Public ContactAlexandrea MacPherson
Outcome results
None listed